Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Feldman

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of Law and the Biosciences|May 4, 2026
Tear down the wall: why requiring the FDA and the PTO to share information will improve the decision-making of both agenciesRobin Feldman, Gideon Schor
The New England Journal of Medicine|March 2, 2017
A Citizen's Pathway Gone Astray - Delaying Competition from Generic DrugsRobin Feldman, Connie Wang
The New England Journal of Medicine|December 30, 2011
Copyright and open access at the bedsideJohn C Newman, Robin Feldman
Journal of Law and the Biosciences|October 25, 2016
Universities and Patent DemandsAndrew K Cordova, Robin Feldman
Health Affairs Scholar|June 11, 2026
Modification patents across multiple NDAs in pharmaceutical protectionsRobin Feldman, Ramy Alsaffar, Tanziuzzaman Sakib
Nature Biotechnology|June 16, 2026
Reply to 'Methodological concerns and a lack of evidence for reforming regulatory exclusivities for pharmaceuticals'Robin Feldman, Gideon Schor, Ramy Alsaffar
Nature Biotechnology|June 16, 2025
The New Clinical Investigation exclusivity: a substantial source of monopoly time for brand drugsRobin Feldman, Gideon Schor, Ramy Alsaffar
Annals of Internal Medicine|March 21, 2022
A Patient Price Guide for Prescription MedicationRobin Feldman, Natalie Feldman, Enrique Seoane-Vazquez
Journal of Health Politics, Policy and Law|May 16, 2022
Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry ConsolidationRobin Feldman, Brent D Fulton, Jamie R Godwin, et al.
The American Journal of Clinical Nutrition|April 3, 2016
Reply to G-C Chen et alLiana C Del Gobbo, Michael C Falk, Robin Feldman, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Law and the Biosciences|May 4, 2026
Tear down the wall: why requiring the FDA and the PTO to share information will improve the decision-making of both agenciesRobin Feldman, Gideon Schor
The New England Journal of Medicine|March 2, 2017
A Citizen's Pathway Gone Astray - Delaying Competition from Generic DrugsRobin Feldman, Connie Wang
The New England Journal of Medicine|December 30, 2011
Copyright and open access at the bedsideJohn C Newman, Robin Feldman
Journal of Law and the Biosciences|October 25, 2016
Universities and Patent DemandsAndrew K Cordova, Robin Feldman
Health Affairs Scholar|June 11, 2026
Modification patents across multiple NDAs in pharmaceutical protectionsRobin Feldman, Ramy Alsaffar, Tanziuzzaman Sakib
Nature Biotechnology|June 16, 2026
Reply to 'Methodological concerns and a lack of evidence for reforming regulatory exclusivities for pharmaceuticals'Robin Feldman, Gideon Schor, Ramy Alsaffar
Nature Biotechnology|June 16, 2025
The New Clinical Investigation exclusivity: a substantial source of monopoly time for brand drugsRobin Feldman, Gideon Schor, Ramy Alsaffar
Annals of Internal Medicine|March 21, 2022
A Patient Price Guide for Prescription MedicationRobin Feldman, Natalie Feldman, Enrique Seoane-Vazquez
Journal of Health Politics, Policy and Law|May 16, 2022
Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry ConsolidationRobin Feldman, Brent D Fulton, Jamie R Godwin, et al.
The American Journal of Clinical Nutrition|April 3, 2016
Reply to G-C Chen et alLiana C Del Gobbo, Michael C Falk, Robin Feldman, et al.
Pageof 3